MMP9 and neoplasm: To further validate the involvement of the PROS1-AXL axis in the upregulation of macrophage MMP9 via MICA+ tumor cells, we introduced the AXL inhibitor cabozantinib to macrophages stimulated via recombinant human PROS1 protein and co-cultured with IRF1+ Huh7 cells.